MRI Guided Focused Ultrasound-Mediated Delivery of Therapeutic Cells to the Brain: A Review of the State-of-the-Art Methodology and Future Applications

Overview

Journal Front Neurol

Specialty Neurology

Date 2021 Jul 5

PMID 34220679

Citations 10

Authors

Nabid Ahmed

Dheeraj Gandhi

Elias R Melhem

Victor Frenkel

Affiliations

Soon will be listed here.

Abstract

Stem cell and immune cell therapies are being investigated as a potential therapeutic modality for CNS disorders, performing functions such as targeted drug or growth factor delivery, tumor cell destruction, or inflammatory regulation. Despite promising preclinical studies, delivery routes for maximizing cell engraftment, such as stereotactic or intrathecal injection, are invasive and carry risks of hemorrhage and infection. Recent developments in MRI-guided focused ultrasound (MRgFUS) technology have significant implications for treating focal CNS pathologies including neurodegenerative, vascular and malignant processes. MRgFUS is currently employed in the clinic for treating essential tremor and Parkinson's Disease by producing precise, incisionless, transcranial lesions. This non-invasive technology can also be modified for non-destructive applications to safely and transiently open the blood-brain barrier (BBB) to deliver a range of therapeutics, including cells. This review is meant to familiarize the neuro-interventionalist with this topic and discusses the use of MRgFUS for facilitating cellular delivery to the brain. A detailed and comprehensive description is provided on routes of cell administration, imaging strategies for targeting and tracking cellular delivery and engraftment, biophysical mechanisms of BBB enhanced permeability, supportive proof-of-concept studies, and potential for clinical translation.

Citing Articles

MRI-guided focused ultrasound for treating Parkinson's disease with human mesenchymal stem cells.

Wu S, Tsai C, Mir A, Hynynen K Sci Rep. 2025; 15(1):2029.

PMID: 39815002 PMC: 11735764. DOI: 10.1038/s41598-025-85811-8.

Cell therapy for neurological disorders.

Svendsen S, Svendsen C Nat Med. 2024; 30(10):2756-2770.

PMID: 39407034 DOI: 10.1038/s41591-024-03281-3.

CAR-T Cells in the Treatment of Nervous System Tumors.

Testa U, Castelli G, Pelosi E Cancers (Basel). 2024; 16(16).

PMID: 39199683 PMC: 11352247. DOI: 10.3390/cancers16162913.

Strategies to Improve Drug Delivery Across the Blood-Brain Barrier for Glioblastoma.

Narsinh K, Perez E, Haddad A, Young J, Savastano L, Villanueva-Meyer J Curr Neurol Neurosci Rep. 2024; 24(5):123-139.

PMID: 38578405 PMC: 11016125. DOI: 10.1007/s11910-024-01338-x.

An introductory review of post-resection chemotherapeutics for primary brain tumors.

McGovern M, Scanlon M, Stanton A, Lucke-Wold B Explor Target Antitumor Ther. 2023; 4(3):537-544.

PMID: 37455829 PMC: 10344890. DOI: 10.37349/etat.2023.00150.

References

Zhu J, Zhou L, XingWu F . Tracking neural stem cells in patients with brain trauma. N Engl J Med. 2006; 355(22):2376-8. DOI: 10.1056/NEJMc055304. View

Abrahao A, Meng Y, Llinas M, Huang Y, Hamani C, Mainprize T . First-in-human trial of blood-brain barrier opening in amyotrophic lateral sclerosis using MR-guided focused ultrasound. Nat Commun. 2019; 10(1):4373. PMC: 6763482. DOI: 10.1038/s41467-019-12426-9. View

Portnow J, Synold T, Badie B, Tirughana R, Lacey S, DApuzzo M . Neural Stem Cell-Based Anticancer Gene Therapy: A First-in-Human Study in Recurrent High-Grade Glioma Patients. Clin Cancer Res. 2016; 23(12):2951-2960. PMC: 8843778. DOI: 10.1158/1078-0432.CCR-16-1518. View

Thomsen G, Avalos P, Ma A, Alkaslasi M, Cho N, Wyss L . Transplantation of Neural Progenitor Cells Expressing Glial Cell Line-Derived Neurotrophic Factor into the Motor Cortex as a Strategy to Treat Amyotrophic Lateral Sclerosis. Stem Cells. 2018; 36(7):1122-1131. DOI: 10.1002/stem.2825. View

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

Burgess A, Shah K, Hough O, Hynynen K . Focused ultrasound-mediated drug delivery through the blood-brain barrier. Expert Rev Neurother. 2015; 15(5):477-91. PMC: 4702264. DOI: 10.1586/14737175.2015.1028369. View

Pollock K, Dahlenburg H, Nelson H, Fink K, Cary W, Hendrix K . Human Mesenchymal Stem Cells Genetically Engineered to Overexpress Brain-derived Neurotrophic Factor Improve Outcomes in Huntington's Disease Mouse Models. Mol Ther. 2016; 24(5):965-77. PMC: 4881765. DOI: 10.1038/mt.2016.12. View

van Linde M, Brahm C, de Witt Hamer P, Reijneveld J, Bruynzeel A, Vandertop W . Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis. J Neurooncol. 2017; 135(1):183-192. PMC: 5658463. DOI: 10.1007/s11060-017-2564-z. View

Zhu L, Huang Y, Lam D, Gach H, Zoberi I, Hallahan D . Targetability of cervical cancer by magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU)-mediated hyperthermia (HT) for patients receiving radiation therapy. Int J Hyperthermia. 2021; 38(1):498-510. DOI: 10.1080/02656736.2021.1895330. View

10.

Okuma Y, Wang F, Toyoshima A, Kameda M, Hishikawa T, Tokunaga K . Mannitol enhances therapeutic effects of intra-arterial transplantation of mesenchymal stem cells into the brain after traumatic brain injury. Neurosci Lett. 2013; 554:156-61. DOI: 10.1016/j.neulet.2013.08.058. View

11.

Staerk J, Dawlaty M, Gao Q, Maetzel D, Hanna J, Sommer C . Reprogramming of human peripheral blood cells to induced pluripotent stem cells. Cell Stem Cell. 2010; 7(1):20-4. PMC: 2917234. DOI: 10.1016/j.stem.2010.06.002. View

12.

Mehta R, Rezvani K . Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer. Front Immunol. 2018; 9:283. PMC: 5818392. DOI: 10.3389/fimmu.2018.00283. View

13.

Liu H, Hua M, Yang H, Huang C, Chu P, Wu J . Magnetic resonance monitoring of focused ultrasound/magnetic nanoparticle targeting delivery of therapeutic agents to the brain. Proc Natl Acad Sci U S A. 2010; 107(34):15205-10. PMC: 2930577. DOI: 10.1073/pnas.1003388107. View

14.

McMahon D, Bendayan R, Hynynen K . Acute effects of focused ultrasound-induced increases in blood-brain barrier permeability on rat microvascular transcriptome. Sci Rep. 2017; 7:45657. PMC: 5379491. DOI: 10.1038/srep45657. View

15.

Lai R, Yeo R, Lim S . Mesenchymal stem cell exosomes. Semin Cell Dev Biol. 2015; 40:82-8. DOI: 10.1016/j.semcdb.2015.03.001. View

16.

Provenzale J, Silva G . Uses of nanoparticles for central nervous system imaging and therapy. AJNR Am J Neuroradiol. 2009; 30(7):1293-301. PMC: 7051551. DOI: 10.3174/ajnr.A1590. View

17.

Park S, Kim M, Jung H, Chang W, Choi H, Rachmilevitch I . Safety and feasibility of multiple blood-brain barrier disruptions for the treatment of glioblastoma in patients undergoing standard adjuvant chemotherapy. J Neurosurg. 2020; 134(2):475-483. DOI: 10.3171/2019.10.JNS192206. View

18.

Jordao J, Thevenot E, Markham-Coultes K, Scarcelli T, Weng Y, Xhima K . Amyloid-β plaque reduction, endogenous antibody delivery and glial activation by brain-targeted, transcranial focused ultrasound. Exp Neurol. 2013; 248:16-29. PMC: 4000699. DOI: 10.1016/j.expneurol.2013.05.008. View

19.

Matsushita T, Kibayashi T, Katayama T, Yamashita Y, Suzuki S, Kawamata J . Mesenchymal stem cells transmigrate across brain microvascular endothelial cell monolayers through transiently formed inter-endothelial gaps. Neurosci Lett. 2011; 502(1):41-5. DOI: 10.1016/j.neulet.2011.07.021. View

20.

Thompson M, Mei S, Wolfe D, Champagne J, Fergusson D, Stewart D . Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: An updated systematic review and meta-analysis. EClinicalMedicine. 2020; 19:100249. PMC: 6970160. DOI: 10.1016/j.eclinm.2019.100249. View